322 related articles for article (PubMed ID: 34644545)
1. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.
Seo BA; Kim D; Hwang H; Kim MS; Ma SX; Kwon SH; Kweon SH; Wang H; Yoo JM; Choi S; Kwon SH; Kang SU; Kam TI; Kim K; Karuppagounder SS; Kang BG; Lee S; Park H; Kim S; Yan W; Li YS; Kuo SH; Redding-Ochoa J; Pletnikova O; Troncoso JC; Lee G; Mao X; Dawson VL; Dawson TM; Ko HS
Neuron; 2021 Dec; 109(23):3758-3774.e11. PubMed ID: 34644545
[TBL] [Abstract][Full Text] [Related]
2. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
4. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
5. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.
Suzuki M; Fujikake N; Takeuchi T; Kohyama-Koganeya A; Nakajima K; Hirabayashi Y; Wada K; Nagai Y
Hum Mol Genet; 2015 Dec; 24(23):6675-86. PubMed ID: 26362253
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
Stojkovska I; Krainc D; Mazzulli JR
Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
[TBL] [Abstract][Full Text] [Related]
8. Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS.
Bendikov-Bar I; Rapaport D; Larisch S; Horowitz M
Orphanet J Rare Dis; 2014 Jun; 9():86. PubMed ID: 24935484
[TBL] [Abstract][Full Text] [Related]
9. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
10. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
[TBL] [Abstract][Full Text] [Related]
11. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
12. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
13. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
[TBL] [Abstract][Full Text] [Related]
14. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
15. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
[TBL] [Abstract][Full Text] [Related]
16. The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.
Polinski NK; Martinez TN; Ramboz S; Sasner M; Herberth M; Switzer R; Ahmad SO; Pelligrino LJ; Clark SW; Marcus JN; Smith SM; Dave KD; Frasier MA
Dis Model Mech; 2022 Jun; 15(6):. PubMed ID: 35419585
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism.
Baden P; Perez MJ; Raji H; Bertoli F; Kalb S; Illescas M; Spanos F; Giuliano C; Calogero AM; Oldrati M; Hebestreit H; Cappelletti G; Brockmann K; Gasser T; Schapira AHV; Ugalde C; Deleidi M
Nat Commun; 2023 Apr; 14(1):1930. PubMed ID: 37024507
[TBL] [Abstract][Full Text] [Related]
18. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
Mazzulli JR; Xu YH; Sun Y; Knight AL; McLean PJ; Caldwell GA; Sidransky E; Grabowski GA; Krainc D
Cell; 2011 Jul; 146(1):37-52. PubMed ID: 21700325
[TBL] [Abstract][Full Text] [Related]
19. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
